Company Performance Metrics
Peplin is a development-stage specialty pharmaceutical company focused on advancing and commercializing medical dermatology products.
The Company is developing PEP005 (ingenol mebutate) (PEP005), which is derived from Euphorbia peplus (E. peplus), a plant referred to as petty spurge or radium weed. Peplin’s lead product candidate, which is in
Phase III clinical trials, is a patient-applied topical gel containing PEP005, a compound used for the treatment of actinic keratosis (AK). Peplin’s other product candidate is a physician-applied topical gel for the treatment of superficial basal cell carcinoma (superficial BCC), PEP005 Gel for BCC. The active compound in each product is a small molecule extracted and purified from the sap of E. peplus.
On October 16, 2008, the Company acquired Neosil, Inc., a dermatology-focused company. Later on, Peplin, Inc. was acquired by LEO Pharma A/S.
